Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32471278    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32471278 :   free

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19 #MMPMID32471278
  • Orienti I; Gentilomi GA; Farruggia G
  • Int J Mol Sci 2020[May]; 21 (11): ä PMID32471278show ga
  • At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention.
  • |Animals[MESH]
  • |Anti-Inflammatory Agents/pharmacology/*therapeutic use[MESH]
  • |Betacoronavirus/isolation & purification[MESH]
  • |Coronavirus Infections/*drug therapy/pathology/virology[MESH]
  • |Cytokines[MESH]
  • |Fenretinide/pharmacology/*therapeutic use[MESH]
  • |Humans[MESH]
  • |Macrophages/cytology/drug effects/metabolism[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy/pathology/virology[MESH]
  • |Respiratory System/drug effects/metabolism[MESH]
  • |Signal Transduction/drug effects[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    ä 11.21 2020